- Why oncology market access models must evolve
The proliferation of stakeholders makes oncology market access increasingly complex—and successful models increasingly essential. Peter Mansell reports.
9:59am, 7th Sep 2010 - Comprehensive strategies for market access
Alan Crofts outlines the flexible market access strategies needed to address the needs of clinical and non-clinical decision makers.
9:51am, 7th Sep 2010 - Market access: Risk sharing and alternative pricing schemes
Shared-risk agreements can represent uncertain rewards for drug makers and payers. What you need to know before entering into one.
2:33pm, 10th Aug 2010
